Importantly, these observations position ERRγ as a therapeutic target with dual relevance—its inhibition could not only impair MM cell survival but also theoretically attenuate RANKL-driven osteoclast activation, though direct evidence of bone protection in MM models is still needed. Here, ESRRG is linked to Miyoshi myopathy.